ALNY Q3 2019 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$70M+3286.2% YoY

Gross Profit

$65M92.6% margin

Operating Income

-$216M-308.7% margin

Net Income

-$209M-297.6% margin

EPS (Diluted)

$-1.92

QoQ Revenue Growth

+56.7%

Cash Flow

Operating Cash Flow

-$183M

Free Cash Flow

-$219M

Stock-Based Comp.

$46M

Balance Sheet

Total Assets

$2.5B

Total Liabilities

$935M

Stockholders' Equity

$1.6B

Cash & Equivalents

$923M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$70M	$2M	+3286.2%
Gross Profit	$65M	$2M	+3256.5%
Operating Income	-$216M	-$255M	+15.0%
Net Income	-$209M	-$245M	+15.0%

Revenue Segments

Product

$46M100%

Geographic Segments

UNITED STATES

$34M73%

Non-US Or Europe

$12M27%